PRMT7 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia (CML), PRMT7 deletion downregulates glycine decarboxylase expression, disrupting glycine metabolism, leading to methylglyoxal accumulation and selectively eliminating CML stem cells without harming normal hematopoiesis [445].